L:Biopsy™
One-step, High-purity
CTC Separation
Transforming Liquid Biopsy: Where speed meets accuracy,
affordability meets excellence!
Image based
The limitations of imaging-based cancer diagnosis for detecting cancer include the inability to identify crucial genetic signatures relevant to treatment, as demonstrated by a 0% success rate in doing so.
Tissue Biopsy
The challenges associated with tissue biopsy for cancer diagnosis include an overall failure rate, averaging 43%, attributed to inaccessible tissue or technical and human errors. Biopsies also result in patient discomfort, inconvenience, and consume valuable staff time.
ctDNA
Liquid Biopsy
ctDNA assay genotyping is limited by false-negative results, lower sensitivity for fusion events and copy number changes. Use of ctDNA to detect molecular residual disease is not recommended, due to lack of evidence of its clinical utility.
Limitations of Current
Cancer Diagnosis Methods
A lifesaving Advantage:
Early Cancer Detection
Through Liquid Biopsy
Patients may benefit from early detection of cancer through liquid biopsy, enabling them to receive timely treatment and potentially live longer. This early detection, occurring before the tumor progresses significantly, can aid in preventing or controlling the advancement of cancer.
Elevate your
CTC Isolation
Game with
L:Biopsy™
We introduce our groundbreaking application for CTC, L:BiopsyTM, which streamlines the 1st and 2nd enrichment processes into one, resulting in exceptionally high-purity CTC separation. This enables rapid and precise cancer diagnosis, allowing for the isolation of various cell types including CTC clusters, EMT CTCs, and small CTCs within just one week. Moreover, it is offered at an affordable price point to our customers.
STEP
01
Sample
Collection
Initial collection of bodily fluid, typically blood, containing CTCs or ctDNA.
STEP
02
1st Enrichment + 2nd Enrichment
Conventional LB
One Step Enrichment
Streamlined into ONE process by Advanced Lab-on-a-chip Enrichment
The key differentiator of L:Biopsy from traditional Liquid Biopsy lies in its ability to combine the essential 1st and 2nd enrichment steps into a single process, made possible by Lab-on-a-chip technology.
STEP
03
Genomic
Sequencing
Analysis of enriched biomarkers to identify genetic alterations, providing insights into tumor characteristics and potential therapeutic targets.
What makes
L:Biopsy™ so unique?
90%
Purity 
Our application achieves over 90% purity in CTC separation by handling both the 1st and 2nd enrichment steps, typically required in conventional Liquid Biopsy, in a single process.
TAT 
Our application completes the CTC separation process in a single step, significantly reducing the processing time and resulting in a turnaround time of just one week.
Cost
Thanks to our patented technologies, the CTC separation process has been streamlined, resulting in a cost reduction of approximately one-tenth compared to conventional liquid biopsy.
Parallel
Micro-manipulation of CTCs
While we control the desired cells precisely, other cells remain stationary. As a result, the targeted cells we aim to separate are moved to physically segregated spaces. With L:BiopsyTM, we can manipulate thousands of cells simultaneously with precision.
Selective Movement
In the center section of the chip, there is no fluid flow. Only labeled cells are selectively manipulated. WBCs stay still.
Physical Relocation
CTCs are moved to a new physical location, completely separate from previously contaminating white blood cells.
Parallel Operation
Despite its precise nature, tens of thousands of target cells can be manipulated simultaneously.
Testimonials
We have had discussions with several AI startups and Insilico Medicine is the only company which provides excellent service not only with collaboration but also with software license. PandaOmics enabled us to analyze Microarray or RNAseq data easily and quickly. We are satisfied with its usability and the results generated from Insilico’s software. We think PandaOmics is a worthwhile software for target identification. We also greatly appreciate their kind support. They are professionals, and always answer our questions quickly, precisely and kindly.
Dr. Honggil Dong
Lorem ipsum dolor sit am
We have had discussions with several AI startups and Insilico Medicine is the only company which provides excellent service not only with collaboration but also with software license. PandaOmics enabled us to analyze Microarray or RNAseq data easily and quickly. We are satisfied with its usability and the results generated from Insilico’s software. We think PandaOmics is a worthwhile software for target identification. We also greatly appreciate their kind support. They are professionals, and always answer our questions quickly, precisely and kindly.
Dr. Honggil Dong
Lorem ipsum dolor sit am
STEP
01
Sample
Collection
Initial collection of bodily fluid, typically blood, containing CTCs or ctDNA.
